

Please amend page 28, line 1 as follows:

**Claims What is claimed is:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**


1. (Original) A compound of the general formula I:



or pharmaceutically acceptable salt thereof, wherein V is a non-peptidic vector having affinity for the Angiotensin II receptor L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an *in vivo* imaging procedure of a human or animal body.

2. (Original) A compound according to claim 1 wherein V is Losartan, Valsartan, Candesartan, Eprosartan or derivatives thereof.

3. (Currently amended) A compound as claimed in ~~any of the previous claims~~ claim 1, where Z is a chelating agent of Formula II carrying an imageable moiety M




(II)

where:

each R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is independently an R group;

each R group is independently H or C<sub>1-10</sub> alkyl, C<sub>3-10</sub> alkylaryl, C<sub>2-10</sub> alkoxyalkyl, C<sub>1-10</sub> hydroxyalkyl, C<sub>1-10</sub> alkylamine, C<sub>1-10</sub> fluoroalkyl, or 2 or more R groups, together with the atoms to which they are attached form a carbocyclic, heterocyclic, saturated or unsaturated ring.

4. (Currently amended) A compound as claimed in ~~any of the previous claims~~ claim 1, where Z is a chelating agent of formula e carrying an imageable moiety M



5. (Currently amended) A compound as claimed in ~~any of the previous claims~~ claim 1, wherein Z comprises an imaging moiety wherein the imaging moiety comprises metal radionuclides, paramagnetic metal ions, fluorescent metal ions, chromophores, heavy metal ions or cluster ions.

6. (Currently amended) A compound as claimed in ~~claims 3-5~~ claim 3, wherein the imaging moiety comprises <sup>90</sup>Y, <sup>99m</sup>Tc, <sup>111</sup>In, <sup>47</sup>Sc, <sup>67</sup>Ga, <sup>51</sup>Cr, <sup>177m</sup>Sn, <sup>67</sup>Cu, <sup>167</sup>Tm, <sup>97</sup>Ru, <sup>188</sup>Re, <sup>177</sup>Lu, <sup>199</sup>Au, <sup>203</sup>Pb, <sup>141</sup>Ce or <sup>18</sup>F.

7. (Original) A pharmaceutical composition comprising an effective amount of a compound of general Formula (I) or a salt thereof, together with one or more pharmaceutically acceptable adjuvants, excipients or diluents for use in enhancing image contrast in *in vivo* imaging or for treatment of a disease.

8. (Currently amended) Use of a compound as claimed in ~~any one of claims 1 to 6~~ claim 1, in the preparation of a contrast medium for use in a method of diagnosis involving administering said contrast medium to a human or animal body and generating an image of at least part of said body.

9. (Currently amended) A method of generating images of a human or animal body involving administering a contrast agent to said body, and generating an image of at least a part of said body to which said contrast agent has distributed, characterised in that said contrast agent comprises a compound as claimed in ~~any one of claims 1 to 6~~ claim 1.

10. (Currently amended) A method of generating enhanced images of a human or animal body previously administered with a contrast agent composition comprising a compound as claimed in ~~claims 1 to 6~~ claim 1, which method comprises generating an image of at least part of said body.